Evaluate the Safety and Efficacy of Autologous Tumor-infiltrating Lymphocyte in Patients With Refractory Melanoma Who Failed to Immune Checkpoint Inhibitors

NCT07028008 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Melanoma

Interventions

BIOLOGICAL: tumor-infiltrating lymphocyte (TIL)

Sponsor

Samsung Medical Center